Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant anti-PD-1 monotherapy after surgery in HCC with microvascular invasion
ChiCTR2000037530Phase 3Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in hepatocellular carcinoma (HCC) comparing Treatment group (Sintilimab adjuvant) with Observation group (2 arms). Primary endpoints: Recurrence-free survival (RFS) and Overall survival (OS). Planned start Sep 2020; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000037530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037530.